Valsartore Comp

Quick links to important sections

Valsartore Comp

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Valsartore Comp

Property Description
Active Ingredient Valsartan, Hydrochlorothiazide (HCTZ)
Form Oral Tablet (Fixed-Dose Combination)
Pharmacological Class Antihypertensive agents
Common Use Management of elevated blood pressure
Origin Synthetic

What Type of Medicine is Valsartore Comp?

Valsartore Comp is a synthetic prescription medicine classified as an antihypertensive agent, specifically designed for the management of high blood pressure (hypertension). This preparation is delivered as a fixed-dose combination product in a simple oral preparation as a tablet. The combination strategy is clinically recognized as an effective approach when single-drug therapy is insufficient for blood pressure control. This clinical context confirms the medicine's role as a primary tool for controlling arterial pressure in adult patients. Popular combination products containing this formulation include Co-Diovan and various generic fixed-dose combinations.

Active Ingredients: A Dual-Action Combination

Valsartore Comp contains two distinct active ingredients: Valsartan, an Angiotensin II Receptor Blocker (ARB), and Hydrochlorothiazide (HCTZ), a Thiazide Diuretic. These synthetic compounds work together to achieve reliable blood pressure lowering. Valsartan is recognized as an essential cardiovascular medicine and is used to block the effects of the hormone Angiotensin II. The pairing of an ARB with a diuretic is a strategy employed to provide comprehensive pressure control, utilizing their synergistic effect. This dual composition offers a robust pharmacological foundation for managing hypertension effectively, a method supported by numerous pharmacological studies.

General Purpose and Mechanism Principle

The general purpose of Valsartore Comp is to reduce and maintain consistent control over elevated blood pressure. This is achieved through its two primary mechanism principles: the Valsartan component facilitates the widening and relaxation of blood vessels (vasodilation), while the Hydrochlorothiazide component promotes the removal of excess salt and water through increased urination (diuresis). By simultaneously reducing the stiffness of blood vessels and decreasing the overall fluid volume in the circulation, the medicine helps adult patients maintain a healthier, stable circulatory environment. A typical neutral use scenario involves patients requiring consistent, long-term maintenance of their arterial pressure levels.

What side effects are possible with Valsartore Comp?

Valsartore Comp's official safety profile is established by regulatory authorities through categorization of adverse reactions by frequency, the physiological system affected, and specific safety limitations.


Adverse Reaction Scope

  • Key adverse reaction categories: The safety profile includes frequently reported effects such as dizziness and fatigue, alongside potentially serious, though rare, events like Angioedema (swelling) and risks related to electrolyte imbalance.
  • Frequency classification (Common / Uncommon / Rare / Not Known):
    • Common: Dizziness, Fatigue, Nasopharyngitis, Upper respiratory tract infection.
    • Uncommon: Syncope (fainting), Hypotension, Headache, Diarrhea, Nausea, Myalgia (muscle pain).
    • Rare: Hypersensitivity reactions, Angioedema.
    • Frequency Not Known: Renal impairment, Electrolyte imbalances.
  • System-organ classes involved: Nervous System, Vascular System, Metabolism and Nutrition, Gastrointestinal, Musculoskeletal, Renal and Urinary, and Immune System.
  • Serious adverse reactions (as documented in regulatory sources): Angioedema, Severe Symptomatic Hypotension, Acute Renal Failure, and significant Electrolyte Imbalance.
  • Population-specific safety considerations: The medicine is contraindicated for use during pregnancy due to the risk of fetal injury. Caution is necessary in patients with renal or hepatic impairment.
  • Dose- or exposure-related patterns: Hypotension and Dizziness are noted in the SmPC as being more common at the initiation of therapy or during dose escalation.
  • Safety-related restrictions or limitations: The drug is contraindicated in patients with anuria (absence of urine formation) and those with documented hypersensitivity to any component or to sulfonamide-derived drugs (due to the Hydrochlorothiazide component).

Safety Classifications (High-Level)

  • Regulatory frequency framework used: The profile uses the standard frequency classification system (e.g., Common: ge 1/100 to < 1/10) consistent with the EMA and FDA regulatory basis.
  • Regulatory basis: The documented safety information is derived from and consistent with official prescribing documents published by governmental authorities, including the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC).

Connection to the overall safety profile

The official safety information structures the understanding of risks by categorizing adverse reactions based on their documented frequency and the physiological systems affected. By defining serious adverse reactions and outlining explicit population-specific contraindications, the regulatory profile establishes formal boundaries for the medicine’s use. This structure serves to communicate label-derived safety characteristics without interpretation or advisory guidance.

Overdose and Emergency Response

Overdose and When to Seek Help

A Valsartore Comp overdose is primarily associated with excessive hypotension (low blood pressure) resulting from the combined effects of the active ingredients. Documented clinical manifestations of overdose include dizziness, fainting (syncope), and changes in heart rhythm such as tachycardia (rapid heartbeat) or bradycardia (slow heartbeat). The hydrochlorothiazide component may also lead to significant fluid and electrolyte depletion, potentially resulting in abnormalities like hypokalemia (low potassium) or hyponatremia (low sodium).

In severe cases, the official regulatory labeling states that overdose carries a risk of life-threatening consequences, including circulatory collapse and shock. Signs of severe exposure may also include a depressed level of consciousness.

Immediate medical attention is required upon any suspected overdose. Official guidance mandates that individuals seek immediate medical care or contact emergency services and the Poison Control Centre, even if initial signs of discomfort are absent.

Treatment following an overdose is defined as symptomatic and supportive. No specific antidote is available. Management typically involves correcting hypotension, such as by placing the patient in a supine position and administering intravenous fluids. Regulatory documents note that the active ingredients are generally not removed effectively by dialysis. Furthermore, specific regulatory warnings exist for in utero exposure during the second and third trimesters, which is linked to severe neonatal adverse effects including renal failure and hypotension.

Therapeutic Uses of Valsartore Comp

What Valsartore Comp Treats: Main Uses and Benefits

Valsartore Comp, which contains the active substance valsartan, is applied across domains where additional symptomatic support is needed, specifically for conditions presenting with systemic or localized discomfort that affect the cardiovascular system.

Valsartan is relevant in conditions characterized by periods of heightened symptoms, including hypertension (high blood pressure), heart failure (NYHA class II-IV), and managing patients following a myocardial infarction (heart attack).

The medication is considered relevant when supportive symptom management is appropriate, especially in settings marked by temporary physiological imbalance. It may assist with maintaining functional stability and supports general well-being during symptomatic phases. It may help patients cope more steadily with symptom fluctuations.

Valsartore Comp is a combination product, which is commonly used in situations involving certain distressing symptoms. This approach contributes to improved comfort during periods of heightened symptoms and is applied in addressing symptom clusters that create noticeable physiological strain.


Quick Fact: Relevant for symptoms related to heightened physiological activity

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

Official Eligibility Rules for Valsartore Comp

Valsartore Comp (Valsartan/Hydrochlorothiazide) is officially approved for adult patients (ge 18 years) whose blood pressure is not adequately controlled with monotherapy. Eligibility is strictly defined by regulatory documents, listing specific prohibitions and limitations.

Contraindications (Must Not Use):

  • Pregnancy: The medicine is contraindicated during pregnancy (Fetal Toxicity Warning) and must be discontinued immediately if pregnancy is detected.
  • Severe Organ Impairment: Patients with anuria (no urine production), severe renal impairment ( GFR < 30 mL/min), or severe hepatic impairment must not use this medicine.
  • Hypersensitivity: Contraindicated in those with known allergy to any component, including other sulfonamide-derived drugs.
  • Aliskiren Coadministration: Prohibited for use alongside Aliskiren in patients with Diabetes Mellitus.

Restricted and Conditional Use:

  • Pediatric Use: Safety and efficacy have not been established in children and adolescents (lt 18 years).
  • Lactation: Avoid use while breastfeeding; the patient must discontinue either nursing or the drug.
  • Electrolyte Imbalances: Initial therapy is restricted until pre-existing volume/salt depletion or hypokalaemia is corrected.
  • Older Adults: While generally permissible, use requires caution due to increased sensitivity and risk of orthostatic hypotension.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines documented interactions for Valsartore Comp (a combination of an Angiotensin II Receptor Blocker and a Thiazide Diuretic) with other medicinal products and substances.

Contraindicated and Not Recommended Combinations

Classification Interacting Substance/Class Rationale
Contraindicated Aliskiren Increased risk of hyperkalemia and renal function deterioration in patients with diabetes or moderate-to-severe renal impairment
Not Recommended Potassium Supplements & Potassium-Sparing Diuretics Substantially increased risk of hyperkalemia (high blood potassium)
Not Recommended Lithium Preparations Decreased renal clearance of Lithium, leading to a high risk of Lithium toxicity

Other Clinically Significant Interactions

  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): These medicines may reduce the blood pressure-lowering and diuretic effects of Valsartore Comp and can increase the risk of worsening kidney function.
  • Cholestyramine and Colestipol: These resins reduce the absorption of the diuretic component. A timing separation of at least 4 hours before or after taking the resins is necessary.
  • Alcohol, Barbiturates, and Narcotics: Co-administration may enhance the risk of orthostatic hypotension (dizziness upon standing).
  • Antidiabetic Agents: The diuretic component may necessitate an adjustment in the dosage of insulin or oral antidiabetic drugs due to potential alterations in glucose tolerance.

Mechanism of Action

Valsartan, the angiotensin II receptor blocker component, acts as a competitive antagonist primarily at the Angiotensin II Type 1 (AT1) receptors. These receptors are expressed across various tissues, notably vascular smooth muscle, the adrenal gland, and kidney. By selectively binding to the AT1 receptor, valsartan prevents the endogenous ligand, angiotensin II, from initiating its signaling cascade. This blockade is specific and does not affect the AT2 receptor subtype or the activity of the angiotensin-converting enzyme (ACE). The subsequent intracellular consequence of AT1 receptor inhibition is the attenuation of Gq protein-coupled pathways, which normally mediate vasoconstriction and aldosterone synthesis. Downstream cascades, including the ERK1/2 pathway, are inhibited, leading to reduced cellular proliferation and hypertrophy in target tissues. System-level physiological modulation involves reduced peripheral vascular resistance due to arterial and venous vasodilation, decreased circulating aldosterone concentration, and reduced renal sodium and water reabsorption. These actions collectively modulate systemic vascular tone and fluid balance.

Dosage and Administration Information

Valsartore Comp is an oral medication that can be taken with or without food, as directed by a healthcare professional. It is typically administered once or twice daily, and the daily timing should be kept consistent.

Official Dosing and Administration

Indication Starting Dose Maintenance Dose Range Administration Frequency
Adult Hypertension 80 mg or 160 mg 80 mg to 320 mg Once daily
Adult Heart Failure 40 mg 40 mg to 160 mg Twice daily
Adult Post-MI 20 mg 20 mg to 160 mg Twice daily

For adults with Heart Failure or following a Myocardial Infarction (Post-MI), the dose is gradually increased, or titrated, to the highest level tolerated by the patient, up to 160 mg twice daily. Adjustments to the dose of concomitant diuretics may also be considered in heart failure patients.

Age-Specific and Preparation Rules

  • Pediatric Use: The medication is not recommended for children under 6 years of age. For children aged 6 to 16 with hypertension, the usual starting dose is 1.3 mg/kg once daily, up to 40 mg total, with dose adjustments based on blood pressure response.
  • Oral Suspension: An oral suspension form is recommended for patients, particularly children, who cannot swallow the tablets or for whom the calculated dose does not match tablet strengths. The oral suspension and tablets are not substitutable on a milligram-per-milligram basis due to differences in systemic exposure; dose adjustment may be necessary when switching forms.
  • Missed Dose: If a dose is missed, it should be taken as soon as the patient remembers, unless it is nearly time for the next scheduled dose. In this case, the missed dose should be skipped, and the patient should resume the regular schedule. Do not take two doses to compensate for a missed dose.

Recent Clinical Evidence

Evidence for Use in Managing High Blood Pressure (Hypertension)

Research exploring how symptoms change over time for Valsartore Comp (Valsartan/HCTZ) is built primarily on randomized controlled trials (RCTs) designed to examine blood pressure measurements in adult patients. Studies compared the combination against an inactive placebo and the individual monotherapies. Trials reported measurements associated with blood pressure changes when compared to the results measured for the individual monotherapies. Research highlights changes measured during the study period related to participants reaching specific blood pressure goals over short-term intervals of 8 to 12 weeks.

Comparative Performance in Clinical Trials

Certain studies reported that blood pressure measurements observed in the combination group differed when compared to strategies like increasing the high-dose diuretic alone. Furthermore, post-marketing studies have monitored how the combination compares to other dual-treatment options, with research describing patterns among the different treatment groups.

Long-Term Research and Outcomes Tracked

The sustained measurements of Valsartore Comp have been explored through open-label extension studies that followed participants for up to a year or more. For understanding longer-term health outcomes, the evidence structure relies on data from major clinical trials involving the Valsartan component. These long-term studies were designed to examine outcomes related to cardiovascular events, such as stroke, in high-risk patients.

Evidence in Specific Patient Groups

Studies monitored Valsartore Comp in various groups, including elderly patients and those with co-existing conditions like diabetes, and reported observations related to changes in blood pressure readings that were similar to the reported measurements in younger adults. However, the combination's safety and effectiveness was not established for the pediatric population.

What is Still Uncertain About the Research Evidence

The evidence base has limitations. The primary focus of many trials was on blood pressure, a surrogate endpoint, and there is limited information for long-term outcomes specifically from studies of the fixed-dose combination itself. Comparative evidence is lacking regarding the medicine's use as a first-line initial therapy, as research often studied the combination in patients whose condition was not adequately controlled on prior single-agent treatments.

Key Studies & References Diovan HCT- valsartan and hydrochlorothiazide tablet, film coated - Label: DailyMed - NIH

Frequently Asked Questions (FAQ)

Common questions about Valsartore Comp (FAQ)


Q: How long does it typically take for Valsartore Comp to start having an effect on blood pressure?

A: Studies indicate that the blood pressure-lowering effect of Valsartore Comp is substantially present within the first two weeks of use. However, the maximum intended antihypertensive effect, or the fullest drop in blood pressure, is generally attained after continuing therapy for two to four weeks following the start of treatment or after a dose change.

Q: Why do some people experience dizziness when starting Valsartore Comp?

A: Dizziness is documented in official sources as a common effect when taking Valsartore Comp. Regulatory documents specifically note that effects like hypotension (low blood pressure) and dizziness are observed more frequently at the initiation of therapy or when a patient’s dose is increased.

Q: Can Valsartore Comp interact with common over-the-counter pain relievers?

A: Official product information mentions an interaction with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), a class that includes many common pain relievers. Co-administration of NSAIDs is associated with a risk of decreased blood pressure-lowering and diuretic effects, and may increase the documented risk of worsening renal (kidney) function.

Q: Does alcohol consumption interfere with how Valsartore Comp works?

A: The official product information documents that co-administration of alcohol may enhance the potential for orthostatic hypotension. This is a sudden drop in blood pressure that can cause dizziness upon standing, and the risk is enhanced due to the diuretic component of Valsartore Comp.

Q: Does Valsartore Comp affect a person's ability to drive or operate machinery?

A: Adverse reactions such as dizziness and fatigue are documented as common when using Valsartore Comp. Official documents include a warning that patients should consider how the medicine affects them before driving vehicles or operating machinery, due to the potential for these side effects.

Q: Is it necessary to have regular blood tests while on Valsartore Comp?

A: Official product information describes the requirement to monitor renal function and potassium levels in patients considered susceptible. Frequent monitoring of serum potassium is specifically recommended in official documents due to the effects of the diuretic component.

Q: Is there a link between Valsartore Comp and a persistent dry cough?

A: Cough is documented in some official regulatory sources as an uncommon adverse reaction associated with the hydrochlorothiazide component. While not a common side effect in its profile, it has been observed in clinical monitoring.

Q: What is the typical duration of treatment with Valsartore Comp?

A: Valsartore Comp is officially indicated for the management of chronic conditions, such as high blood pressure. Official patient information often states that this type of medicine is typically used long-term to help control blood pressure.

Q: Can taking too much Valsartore Comp cause a dangerously low heart rate?

A: Regulatory information concerning overdosage states that the most likely manifestations are hypotension (low blood pressure) and tachycardia (fast heart rate). However, official documents also mention that a slow heart rate, or bradycardia, could also occur.

Q: Is there any research evidence suggesting Valsartore Comp works better for certain ethnic groups?

A: Official regulatory documents explicitly state that the pharmacokinetic differences due to race have not been studied for the combination of Valsartan and Hydrochlorothiazide. Therefore, specific evidence on comparative efficacy across different ethnic groups is not included in the prescribing information.

Q: Can switching to Valsartore Comp from a different medication cause temporary side effects?

A: The product label indicates that certain adverse reactions, such as hypotension and dizziness, are more likely to occur at the initiation of therapy. These temporary effects may therefore be observed when beginning Valsartore Comp, even when switching from another blood pressure treatment.

Q: Can Valsartore Comp be split or crushed, or must it be swallowed whole?

A: Official patient information typically states that the tablets should be swallowed whole and advises not to break, crush, or chew them. This is common guidance for many fixed-dose combination tablets.

Q: Why is Valsartore Comp intended to be a long-term treatment?

A: The general purpose of this medicine is to help control chronic elevated blood pressure, not to provide a cure. Official information states that to maintain stable arterial pressure, this type of treatment is typically used for the long term to control the condition.

Q: What kind of studies support the use of Valsartore Comp for its stated conditions?

A: The evidence supporting the use of Valsartore Comp is based primarily on randomized controlled trials (RCTs). These studies compared the fixed-dose combination against an inactive placebo and the individual components. Additionally, open-label extension studies have been used to track sustained blood pressure measurements.

Q: Is headache a common initial side effect when starting Valsartore Comp?

A: Headache is listed in official documents as an uncommon side effect. While the common effects of dizziness and hypotension are noted to be more frequent at the start of therapy, headache is not specifically mentioned in regulatory sources as being more frequent during the initiation of treatment.

Q: Can men and women experience different side effects from Valsartore Comp?

A: Official pharmacokinetic data indicates that the overall exposure of Valsartan in the body does not differ significantly between males and females. Regulatory safety information does not explicitly define differences in the frequency or types of reported side effects based on gender.

Q: What is the potential impact of Valsartore Comp on liver function?

A: Regulatory warnings state that the medicine should be used with caution in patients with impaired hepatic (liver) function. Postmarketing reports have included observations of elevated liver enzymes and rare instances of hepatitis.

Q: Is Valsartore Comp used for conditions other than high blood pressure?

A: Yes, in addition to high blood pressure (hypertension), Valsartore Comp is officially indicated for adult patients with specific cardiovascular conditions, including Heart Failure and for use after a recent Myocardial Infarction (heart attack).

How should Valsartore Comp be stored and disposed of?

How to Store and Dispose of Valsartore Comp

The storage and disposal requirements for Valsartore Comp (valsartan/hydrochlorothiazide) tablets are set by regulatory bodies to maintain product integrity and ensure public safety.

Official Storage Conditions

Requirement Specification (as per regulatory label)
Temperature Controlled Room Temperature: 15 C to 30 C (59 F to 86 F)
Protection Store away from excess heat, moisture, and direct light. Do not freeze.
Container Rule Keep in the original container and keep the cap tightly closed.
Child Safety Mandatory to keep out of the sight and reach of children.

Disposal Instructions

Official guidance requires disposing of unused or expired Valsartore Comp according to local regulations. Users are directed to consult a healthcare professional or utilize an authorized drug take-back program for the safe disposal of medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Valsartore Comp found in:

A-Z Index: